Novel Targets in Insulin Resistance and Type 2 Diabetes

Article Figures & Data

Figures

  • Figure 1.

    Effects of TAK-875, Glimepiride, and Placebo on Glycemia

    Reproduced from Burant CF et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 21012;379(9824):1403–1411. With permission from Elsevier.
  • Figure 2.

    Effect of Canagliflozin Versus Sitagliptin on HbA1C Levels

    Reproduced from Schernthaner G et al. Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial. Diabetes Care 2013;36(4):908–913. With permission from the American Diabetes Association.